Sanofi, Regeneron Restructure Immuno-Oncology Agreement
07 Enero 2019 - 2:14AM
Noticias Dow Jones
By Anthony Shevlin
Sanofi SA (SAN.FR) said Monday that it and Regeneron
Pharmaceuticals Inc. (REGN) have restructured their global
immuno-oncology discovery and development agreement for new
immuno-oncology cancer treatments.
Under the new terms, Sanofi will pay Regeneron $462
million--which covers the French company's share of program costs
for the last quarter of 2018--and up to $120 million in development
costs for the two selected clinical-stage bispecific
antibodies.
Sanofi will also pay a termination fee for other programs
covered in the original agreement, the company said.
"This provides Sanofi increased flexibility to advance its
early-stage immuno-oncology pipeline independently while Regeneron
retains all rights to its other immuno-oncology discovery and
development programs," said Sanofi.
Regeneron will commit up to $70 million to further develop the
BCMAxCD3 bispecific antibody for multiple myeloma and up to $50
million to further develop the MUC16xCD3 bispecific for mucin-16
expressing cancers, Sanofi said.
Write to Anthony Shevlin at anthony.shevlin@dowjones.com;
@anthony_shevlin
(END) Dow Jones Newswires
January 07, 2019 02:59 ET (07:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
